Scientists show that 6 or 12 months of #adjuvant #icotinib significantly improves DFS, OS, and BMFS in resected stage II–IIIA #EGFR-mutated #NSCLC with good tolerability, supporting icotinib as a post-chemotherapy option. #medsky

#OpenAccess in #STTT: doi.org/10.1038/s413...

This study shows that #adjuvant #Icotinib for 6/12 months after #chemotherapy improves DFS & OS in patients with resected #EGFR-mutated stage II–IIIA #NSCLC, with manageable safety, supporting it as a potential treatment option. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...